STOCK TITAN

ResMed (RMD) Stock Price, News & Analysis

RMD NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
6 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-9.1% close of October 30, 2026
1-year change
-3.4% closing prices, November 20, 2025 to November 20, 2026
1-month change
-4% closing prices, October 20, 2026 to November 20, 2026

Company Description

ResMed Inc. (NYSE: RMD, ASX: RMD) is a health technology company that focuses on sleep, breathing, and care delivered in the home. According to the company’s public statements, ResMed "creates life-changing health technologies" and aims to empower people in more than 140 countries to live happier, healthier lives. Its work centers on sleep health and breathing health, with a vision of enabling care to be delivered in patients’ own homes rather than only in traditional clinical settings.

ResMed is described in its filings as a U.S. corporation with common stock listed on the New York Stock Exchange under the symbol RMD. It is also represented on the Australian Securities Exchange through CHESS Depositary Interests. The company is associated with the surgical and medical instrument manufacturing industry and operates in the broader manufacturing sector.

Across multiple investor and press materials, ResMed emphasizes its AI-powered digital health solutions, cloud-connected devices, and intelligent software. These technologies are intended to make home healthcare more personalized, accessible, and effective. ResMed highlights that its connected ecosystem includes cloud-connected devices and digital tools that support sleep and breathing therapy, and that these offerings are used in out-of-hospital and home-care environments.

The company describes itself as a health technology leader focused on sleep, breathing, and home-based care. It references a mission to help people "sleep better, breathe better and live longer and healthier" with care provided in their own home. ResMed’s communications also refer to a 2030 mission to help large numbers of people live healthier, higher-quality lives through better sleep and breathing health, supported by healthcare technology delivered at home.

In addition to devices and software, ResMed’s public materials describe a broader sleep-health ecosystem. Examples include the myAir consumer sleep companion app, the AirSense device platforms, and features such as Dawn, described as a generative AI-powered sleep health assistant. The company also refers to residential care software (sometimes described as SaaS) and digital diagnostic pathways that connect awareness, testing, and treatment for sleep health conditions.

ResMed’s communications highlight its focus on obstructive sleep apnea (OSA) and other sleep and respiratory conditions. The company has supported and published research on the prevalence and burden of OSA, including studies in The Lancet Respiratory Medicine projecting growth in OSA among U.S. adults. These studies are used by ResMed to underscore the need for earlier diagnosis, scalable care pathways, and long-term treatment strategies for sleep-related breathing disorders.

The company also emphasizes clinical evidence and real-world data as part of its approach. For example, it has described meta-analyses showing that treating OSA with CPAP therapy can reduce the risk of death, and it has highlighted retrospective real-world evidence related to therapy adherence and comfort settings on its devices. ResMed states that it uses de-identified, real-world sleep data and machine-learning algorithms to support personalized therapy features, while noting that these efforts are developed with clinical oversight and ethical data use.

ResMed presents itself as active in product design and intellectual property. It has publicly reported reaching a global portfolio of 10,000 patents and designs, granted or pending, and has announced design awards such as dual Red Dot Product Design awards for its AirTouch N30i nasal cradle mask. These communications frame the company’s product development as focused on patient comfort, adherence to therapy, and human-centered design.

Beyond products and software, ResMed has launched initiatives such as the Sleep Institute, described as a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute is presented as publishing original research, expert perspectives, and real-world data to inform care innovation, policy decisions, and system-level strategies that elevate sleep as a global health priority.

From a corporate governance perspective, ResMed’s SEC filings show it operates with a board of directors elected by stockholders, and it maintains equity-based incentive plans and an employee stock purchase plan, as reflected in amendments approved at its 2025 annual meeting of stockholders. The company also declares regular cash dividends, as disclosed in its periodic Form 8-K filings, and communicates its financial performance and strategic priorities through earnings releases and investor webcasts.

Overall, ResMed’s publicly available descriptions portray a company that combines medical devices, digital health software, AI-driven tools, and research initiatives to address sleep and respiratory health needs, with an emphasis on home-based care and large-scale, data-informed approaches to diagnosis, treatment, and ongoing therapy support.

Stock Performance

$235.63
+0.00%
+0.00
After hoursChange vs the $235.63 closeLast updated: at
-3.4%
Performance 1 year
$33.1B
140.7M
Shares outstanding As of October 26, 2026.

ResMed (RMD) closed at $235.63 on November 20, 2026. Over the past 12 months, the price has lost 3.4%.

See what a $1,000 investment in RMD would be worth today

Average down calculator for RMD

RMD Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

SEC Filings

ResMed has filed 10 recent SEC filings, including 10 Form 4. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all RMD SEC filings →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
11,783
Shares Sold
5
Transactions
Most Recent Transaction
De Witte Jan (Director) sold 429 shares @ $237.00 on November 17, 2026

Insider selling at ResMed over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

ResMed generated $5.7B in revenue in FY2026, retaining a 61.1% gross margin, operating income reached $1.9B (33.4% operating margin), and net income was $1.5B, reflecting a 26.9% net profit margin. Diluted earnings per share stood at $10.43. The company generated $1.8B in operating cash flow. The current ratio was 3.10, measuring current assets divided by current liabilities.

$5.7B
Revenue (FY2026)
$1.5B
Net Income (FY2026)
$1.8B
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Operations

Greenwood distribution center opens

Greenwood, IN hub to begin operations in 2027; >100 jobs; boosts 2-day coverage to 90%

ResMed has 1 upcoming scheduled event. The next event, "Greenwood distribution center opens", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the RMD stock price.

Short Interest History

Last 12 Months

Short interest in ResMed (RMD) currently stands at 10.5 million shares, down 12.2% from the previous reporting period, representing 7.5% of the float.

Days to Cover History

Last 12 Months

Days to cover for ResMed (RMD) currently stands at 7.0 days, down 42.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 36.5%. Across the settlements charted above, it has ranged from 6.9 to 14.2 days.

RMD Company Profile & Sector Positioning

ResMed (RMD) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NYSE. Among dividend-paying stocks, RMD ranks #1,683 by dividend yield.

Investors comparing RMD often look at related companies in the same sector, including Alcon Inc. (ALC), West Pharmaceutical Services, Inc. (WST), Becton, Dickinson and Co. (BDX), Medline (MDLN), and Baxter International Inc. (BAX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RMD's relative position within its industry.

Frequently Asked Questions

The current stock price of ResMed (RMD) is $235.63 in after-hours trading as of November 20, 2026.

The market cap of ResMed (RMD) is approximately $33.1B. Learn more about what market capitalization means .

The FY2026 revenue of ResMed (RMD) is $5.7B, from its most recent completed fiscal year.

The FY2026 net income of ResMed (RMD) is $1.5B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of ResMed (RMD) is $10.43 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of ResMed (RMD) is $1.8B for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of ResMed (RMD) is 26.9% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of ResMed (RMD) is 33.4% for FY2026, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of ResMed (RMD) is 61.1% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of ResMed (RMD), current assets divided by current liabilities, was 3.10 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of ResMed (RMD) is $3.5B for FY2026, its most recent completed fiscal year.

The operating income of ResMed (RMD) is $1.9B for FY2026, its most recent completed fiscal year. Learn about operating income.

ResMed Inc. focuses on sleep, breathing, and care delivered in the home. According to its public statements, the company creates health technologies that include AI-powered digital health solutions, cloud-connected devices, and intelligent software designed to make home healthcare more personalized, accessible, and effective.

ResMed is associated with the surgical and medical instrument manufacturing industry within the broader manufacturing sector. Its public communications describe it as a health technology company focused on sleep, breathing, and home-based care.

ResMed’s common stock is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the ticker symbol RMD. The company also has CHESS Depositary Interests that trade on the Australian Securities Exchange, as described in its Form 8-K filings.

ResMed states that it offers AI-powered digital health solutions and has introduced AI-enabled tools such as Smart Comfort, which uses machine-learning algorithms and real-world sleep data to recommend personalized comfort settings for CPAP therapy. The company has also launched Dawn, described as a generative AI-powered sleep health assistant, and notes that AI is embedded across research and development, operational support, and product design.

ResMed’s communications emphasize sleep and breathing health, particularly obstructive sleep apnea (OSA). The company references research estimating that OSA affects large numbers of people globally and highlights the need for earlier diagnosis, preventative strategies, and personalized care. It also refers more broadly to sleep health and breathing health as core areas of focus.

ResMed frequently states that it aims to deliver care in the home, using cloud-connected devices, digital tools, and software to support therapy outside traditional clinical settings. Its vision is that people can achieve better sleep and breathing with care delivered in their own home, supported by connected technologies and data-driven insights.

Yes. ResMed’s Form 8-K filings disclose that its board of directors has declared recurring quarterly cash dividends, for example a dividend of US $0.60 per share with specified record and payment dates. These filings also note that holders of CHESS Depositary Interests on the Australian Securities Exchange receive an equivalent amount in Australian currency based on the exchange rate on the record date.

Sleep Institute is described by ResMed as a global clinical insights initiative established by the company to advance the science and understanding of sleep health. It collaborates with clinicians, researchers, policymakers, and health system leaders to deliver objective, data-driven insights intended to inform care model innovation, support policy development, and reinforce the role of sleep in improving health outcomes.

ResMed highlights that it supports and publishes research on sleep health, including studies in The Lancet Respiratory Medicine on obstructive sleep apnea prevalence and CPAP therapy outcomes. It also notes that some of its AI-enabled features draw on large volumes of de-identified, real-world sleep data to personalize therapy settings, with clinical oversight and attention to ethical data use and privacy laws.

ResMed refers to residential care software, sometimes described as SaaS, and digital platforms such as myAir and other tools that support sleep health and breathing health. The company has discussed building a digital diagnostic pathway from awareness to testing to treatment, using software platforms to help patients get diagnosed earlier and to support homecare providers in managing those patients.